Pharmora* provides assured, global medical review services for the clinical development, marketing and safety surveillance of medical products, from the first clinical trials to ongoing commercialisation.
We deliver the capabilities of a Consultant with the scalability & flexibility of a Service Provider, wrapped in the security of full Quality Assurance.
*At Pharmora we serve our global clients from offices in the UK (Pharmora Ltd) and Ireland (Pharmora Global Solutions Ltd).
Regulatory Agency
If you work for a regulatory agency and require additional support in assessing marketing authorisation applications, click here to learn more about how we can assist you.
What can Pharmora do?
Pharmora is a preferred strategic partner for the following services:
Clinical Development
Pharmora can provide medical and scientific expertise to support your clinical development projects at all phases and through regulatory submission to approval
Patient Safety
Pharmora is built on a foundation of safety expertise throughout the product life cycle
Medical & Regulatory Review
Pharmora can work seamlessly with your team to evaluate the data and ensure the documents accurately convey your key messages
Training and more
Pharmora runs training courses on key skills and can provide bespoke training packages depending on your needs
Where are you in the
Product Life
Cycle?
Pre-clinical
Early clinical development
Phase II-III clinical
development
NDA / MAA submission
Life cycle
management
Our latest thinking
Celebrating the 10th Annual Global Campaign for Patient Safety
Conversations With Industry Leaders : Dr Sheuli Porkess
Dr Jones was delighted to meet with Dr Sheuli Porkess, Director of Actaros Consultancy and President of the Faculty of Pharmaceutical Medicine to talk about some hot topics in our industry! Read on to hear their insights on AI and the challenges of encouraging diversity in our industry…
Hereditary Cancer Awareness Week: Understanding Risk, Empowering Families
Hereditary Cancer Awareness Week raises awareness of inherited cancer risks such as BRCA and Lynch syndrome. Learn how family history, genetic testing, and new research in population screening and polygenic risk scores are shaping the future of cancer prevention.
